All lobbying filings

TODD STRATEGY GROUP

Lobbying for ASTRAZENECA PHARMACEUTICALS LP · â€‹Biopharmaceutical Company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Delaware · House · Senate · $80,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 3

S 864
HELP Copays Act
HR 1672
Maintaining Investments in New Innovation Act
HR 946
ORPHAN Cures Act

Lobbying activity 2

Medicare/Medicaid

340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.

Health Issues

General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Prescription drug pricing policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.